INDIANAPOLIS, Feb. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial …

INDIANAPOLIS, Feb. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial …

Feb 6, 2025 · ELI LILLY AND COMPANY Q4 2024 EARNINGS CALL 02.06.25. 2024 Q4 EARNINGS Introduction and Key Events. Dave Ricks, Chair and Chief Executive Officer. ...

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

INDIANAPOLIS, Feb. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial …

Feb 6, 2025 · Eli Lilly (LLY-1.07%) Q4 2024 Earnings Call Feb 06, 2025, 10:00 a.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator. …

Feb 7, 2025 · Eli Lilly and Co reported a 32% increase in full-year revenue for 2024, exceeding guidance by $4 billion. The company achieved a 45% revenue growth in Q4 2024, driven by …

Feb 6, 2025 · Eli Lilly (LLY) reported strong Q4 2024 financial results with revenue increasing 45% to $13.53 billion, primarily driven by Mounjaro and Zepbound sales.Q4 EPS grew 102% …

INDIANAPOLIS, Feb. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial …

Feb 6, 2025 · Eli Lilly and Company (NYSE: LLY) today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial guidance. ... Revenue in Q4 2024 increased …